-
WASHINGTON, D.C. — A novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, including one patient who achieved complete remission, according to data from two phase I clinical trials presented at the AACR Annual Meeting 2013, held in Washington...
Posted to
News
by
AACR News
on
Sat, Apr 6 2013
Filed under:
Filed under: Press Releases, Cancer, Media Materials, AACR, American Association for Cancer Research, immune system, Clinical trial, immunotherapy, 2013 Annual Meeting, personalized vaccine, T-cell therapy, ovarian, Annual Meeting 2013, dendritic cell, Dr. Lana Kandalaft, advanced stage
-
Discussions of cancer clinical trials with black patients were shorter in length. These data may explain under-enrollment of black patients in cancer clinical trials. SAN DIEGO — A study comparing how physicians discuss clinical trials during clinical interactions with black patients versus white...
Posted to
News
by
AACR News
on
Sun, Oct 28 2012
Filed under:
Filed under: Press Releases, Research, Conference, Communication, Cancer, Media Materials, AACR, American Association for Cancer Research, minorities, Disparities, cancer health disparities, Clinical trial, The Science of Cancer Health Disparities, physician-patient communication, under-enrollment, clinical cancer trials, Dr. Susan Eggly
-
AMH is a relatively new blood test which is very useful in checking the ovarian reserve of women. It allows us to estimate the quantity and quality of eggs left in your ovaries, so can get a better idea of how you will respond to superovulation. Basically, it allows us to check how young your ovaries...
-
Clear Passage uses a wide variety of clever techniques in order to lure patients. They claim to be able to treat lots of conditions , ranging from chronic pelvic pain to adhesions to blocked tubes . ( This is smart, because the more the number of conditions you claim to be able treat, the greater the...
-
Combining erlotinib with bevacizumab, capecitabine and radiation is well tolerated by pancreatic cancer patients. Treatment enabled some patients with previously unresectable tumors to have their tumors surgically removed. The encouraging median survival indicates the combination has promise as a potential...
Posted to
News
by
AACR News
on
Tue, Jun 19 2012
Filed under:
Filed under: Press Releases, radiation, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical trial, pancreatic cancer, bevacizumab, Pancreatic Cancer: Progress and Challenges, phase I clinical trial, capecitabine, erlotinib, Dr. Christopher H. Crane
-
See on Scoop.it Dan O’Connor writes: Pharma’s social media future lies in the recruitment of human subjects for research. Slow subject recruitment is one of the biggest barriers to advancements in medical science. Social media presents pharmaceutical companies, both large and small, with two extremely...
-
Final phase III trial analyses substantiate interim results that led to FDA approval. Crossover trial design worked and benefitted patients. Long-term overall survival benefit estimated with no new adverse events. PHILADELPHIA — Patients benefitted from an important design element in the pivotal...
Posted to
News
by
AACR News
on
Fri, Jun 1 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, sunitinib, journal, Clinical trial, Dr. George D. Demetri, gastrointestinal stromal tumor, GIST
-
Galeterone targets prostate cancer through three distinct mechanisms. The drug was well tolerated and safe at all doses tested. Efficacy was demonstrated by PSA decreases and tumor reduction. CHICAGO — Patients with castration-resistant prostate cancer had limited side effects and in many cases...
Posted to
News
by
AACR News
on
Sat, Mar 31 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, Clinical trial, 2012 Annual Meeting, Annual Meeting, AACR Annual Meeting 2012, CRPC, castration-resistant prostate cancer, galeterone, Dr. R. Bruce Montgomery
-
Few topics inspire more rants among drug developers and industry watchers than regulation. To be overly simplistic, industry veterans generally seem to feel that overly conservative regulators are squelching innovation, motivated largely by a desire to cover their own behinds. Critics (I will resist...
Posted to
News
by
Health. Care.
on
Thu, Sep 1 2011
Filed under:
Filed under: health, Medicine, Pharma & Healthcare, Innovation & Science, byline=David Shaywitz, Entrepreneurs, University of California San Francisco, Clinical trial, desmond-hellmann, Genentech, Approved drug, Andy Grove
-
The difficulty encountered in drug development is really an example of the broader challenge of research translation: on the one hand, to study a particular phenomenon, and to gain insight, you generally need to be somewhat reductionist and simplify the problem to focus on the question of interest. This...
Posted to
News
by
Health. Care.
on
Fri, Jul 22 2011
Filed under:
Filed under: health, Health care, Pharma & Healthcare, Innovation & Science, byline=David Shaywitz, Innovation, Strategies & Solutions, Physician, Patient, Business, drug development, patient-oriented research, Humpty Dumpty, Clinical trial, translational research, HIV, Abacavir
-
The trial will be conducted at several locations to include the University of California in Los Angeles. There are two different types of macular degeneration, a dry and wet type and this trial is to work with patients who had the dry form of the disorder. The dry form is the less serious...
-
This is not your regular clinical trial as we think of, but rather using soap and mouthwash that contains Chlorhexadine to be given to a patient upon release from the hospital. Hospitals in Los Angeles and Orange County will identify patients with MRSA or staph infections. In addition patients...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Oct 6 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, MRSA, infections, bacteria, clinical trial, UCI Irvine, infectious diseases, staph, Chlorhexadine
-
The trial will be fore 600 postmenopausal women who experienced at least 7 moderate to severe hot flashes per day or at least 50 moderate to severe hot flashes per week. They want some serious flashers here for this one. Information has also been posted on the website for additional information...
-
The procedure has been done for the last 5 years at all the Shriner Hospitals up until the last 5 years ago, so this is not something brand new, and by growing his own skin back it certainly would be better than skin grafts and synthetic skin as this is what the boy will get. This seems like a...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Jul 6 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, My Commentaries, Surgery, Medical Devices, FDA, Data, Wound care, clinical trial, Shriners, Burn, skin treatments
-
The company is located in Israel with an office here in the US in Waltham, Massachusetts. Most drugs that are available for treating psoriasis are expensive biotech drugs and the company is attempting to create a drug that will be affordable and it is also showing a response to Dry Eye Syndrome...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Jun 8 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, FDA, clinical trial, psoriasis, dry skin, CanFite, Dry Eye, anti inflamatory